Healthcare / Medical DevicesASX
$0.06
+0.00 (+5.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-5.4M · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-94.4%
↓Gross Margin
71.6%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+9.3%
FCF CAGR
—
FCF margin
-105.0%
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.1M · net income $-5.9M · FCF $-5.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.1M | $5.1M | $5.4M | $4.4M | $3.9M |
| Net Income | $-5.9M | $-5.9M | $-5.6M | $-6.1M | $-3.6M |
| EBITDA | $-5.0M | $-5.0M | $-5.1M | $-5.6M | $-3.3M |
| EPS | -0.04 | -0.04 | -0.06 | -0.06 | — |
| Gross Margin | 71.6% | 71.6% | 64.5% | 54.8% | 63.6% |
| Operating Margin | -138.3% | -138.3% | -115.7% | -150.8% | -104.0% |
| Net Margin | -115.3% | -115.3% | -103.6% | -139.3% | -90.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.02 | 0.02 | 0.00 |
| Current Ratio | 2.22 | 2.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.4M | $-5.4M | $-5.0M | $-7.0M | $-4.0M |
| Returns | |||||
| ROE | -94.4% | -94.4% | -78.8% | -51.2% | -20.7% |
| Valuation | |||||
| P/B | 1.53 | 1.53 | 1.10 | 1.27 | 3.32 |
| Growth & Yield | |||||
| Revenue Growth | -5.7% | -5.7% | 24.1% | 11.5% | — |
| EPS Growth | 34.1% | 34.1% | 12.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+110.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → -0.04
Residual
+110.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.